易瑞生物
(300942)
| 流通市值：45.00亿 | | | 总市值：45.00亿 |
| 流通股本：4.05亿 | | | 总股本：4.05亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 185,633,642.05 | 109,287,425.22 | 49,342,908.97 | 224,249,109.55 |
| 营业收入 | 185,633,642.05 | 109,287,425.22 | 49,342,908.97 | 224,249,109.55 |
| 二、营业总成本 | 181,665,643.9 | 109,966,393.45 | 55,561,251.36 | 210,280,739.07 |
| 营业成本 | 66,262,171.88 | 38,834,725.78 | 23,502,052.28 | 65,866,774.58 |
| 税金及附加 | 648,235.48 | 468,883.66 | 373,258.43 | 876,429.6 |
| 销售费用 | 42,641,146.45 | 26,000,567.26 | 11,594,548.43 | 44,967,534.44 |
| 管理费用 | 32,813,550.16 | 22,584,485.84 | 10,410,223.57 | 50,257,681.99 |
| 研发费用 | 30,819,335.83 | 19,597,835.06 | 8,238,945.94 | 40,452,354.02 |
| 财务费用 | 8,481,204.1 | 2,479,895.85 | 1,442,222.71 | 7,859,964.44 |
| 其中:利息费用 | 19,676,887.16 | 12,767,166.69 | 6,417,543.56 | 18,666,370.68 |
| 其中:利息收入 | 7,992,244.97 | 5,961,337.82 | 3,900,514.06 | 8,328,421.46 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,681,238.3 | 1,704,458.31 | 903,784.58 | 1,871,304.38 |
| 加:投资收益 | -3,243,496.93 | -2,323,090.92 | -2,089,627.24 | -5,849,539.02 |
| 资产处置收益 | 12,202,445.31 | 171,594.88 | 135,280.15 | 2,283,492.87 |
| 资产减值损失(新) | -149,956.42 | -149,956.42 | - | -2,143,668.7 |
| 信用减值损失(新) | -881,293.06 | -631,631.18 | 1,366,844.92 | -8,040,953.76 |
| 其他收益 | 3,094,291.45 | 2,368,025.44 | 873,863.02 | 18,875,970.9 |
| 四、营业利润 | 16,671,226.8 | 460,431.88 | -5,028,196.96 | 20,964,977.15 |
| 加:营业外收入 | 407,163.55 | 204,534.57 | 8,991.15 | 356,648.58 |
| 减:营业外支出 | 89,936.49 | 19,219.27 | 15,440.06 | 1,632,563.17 |
| 五、利润总额 | 16,988,453.86 | 645,747.18 | -5,034,645.87 | 19,689,062.56 |
| 减:所得税费用 | -1,818,666.01 | -1,244,085.12 | -800,897.98 | 3,069,654.27 |
| 六、净利润 | 18,807,119.87 | 1,889,832.3 | -4,233,747.89 | 16,619,408.29 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 18,807,119.87 | 1,889,832.3 | -4,233,747.89 | 16,619,408.29 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 18,023,048.35 | 2,339,501.77 | -3,346,003.68 | 17,116,524.08 |
| 少数股东损益 | 784,071.52 | -449,669.47 | -887,744.21 | -497,115.79 |
| 扣除非经常损益后的净利润 | 3,728,488.75 | -2,057,468.49 | -5,106,949.55 | -1,778,814.32 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.04 | 0.01 | -0.01 | 0.04 |
| (二)稀释每股收益 | 0.04 | 0.01 | -0.01 | 0.04 |
| 八、其他综合收益 | -108,226.44 | 35,823.62 | -209,889.51 | -171,733.24 |
| 归属于母公司股东的其他综合收益 | -108,226.44 | 35,823.62 | -209,889.51 | -171,733.24 |
| 九、综合收益总额 | 18,698,893.43 | 1,925,655.92 | -4,443,637.4 | 16,447,675.05 |
| 归属于母公司股东的综合收益总额 | 17,914,821.91 | 2,375,325.39 | -3,555,893.19 | 16,944,790.84 |
| 归属于少数股东的综合收益总额 | 784,071.52 | -449,669.47 | -887,744.21 | -497,115.79 |
| 公告日期 | 2025-10-28 | 2025-08-28 | 2025-04-25 | 2025-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |